Physician profile
Harry Kerasidis
NPI 1982665378
$38,823.33
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37K · 2020: $404 · 2021: $1,354 · 2022: $134.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $35,614.85 | 2019 | |
| Allergan, INC. | $480.65 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $468.77 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $204.53 | 2019-2021 | |
| Lundbeck LLC | $191.90 | 2019-2021 | |
| Brainscope Company, INC. | $173.46 | 2019 | |
| Zyla Life Sciences, INC. | $170.62 | 2019 | |
| Ucb, INC. | $155.91 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $136.83 | 2021 | |
| Biogen, INC. | $131.68 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $123.71 | 2021-2022 | |
| Adamas Pharmaceuticals, INC. | $93.99 | 2019-2020 | |
| Lilly USA, LLC | $82.07 | 2019-2022 | |
| Abbvie INC. | $77.85 | 2021-2022 | |
| Mallinckrodt Enterprises LLC | $64.61 | 2019 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $58.42 | 2019 | |
| Merz North America, INC. | $43.72 | 2019 | |
| Avanir Pharmaceuticals, INC. | $43.59 | 2019 | |
| Genzyme Corporation | $42.37 | 2019-2021 | |
| Amgen INC. | $39.87 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $37.87 | 2019-2021 | |
| Acorda Therapeutics, INC | $37.43 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $34.80 | 2020 | |
| Celgene Corporation | $32.74 | 2021 | |
| Vanda Pharmaceuticals INC. | $32.31 | 2021 | |
| Currax Pharmaceuticals LLC | $29.64 | 2021 | |
| Emd Serono, INC. | $23.61 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.02 | 2022 | |
| Shire North American Group INC | $22.39 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $20.50 | 2020 | |
| Amneal Pharmaceuticals LLC | $20.03 | 2019 | |
| Greenwich Biosciences, INC. | $19.52 | 2019 | |
| Ironshore Pharmaceuticals INC. | $18.65 | 2021 | |
| Genentech USA, INC. | $15.77 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.66 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.67 | 2021 | |
| Tris Pharma INC | $13.42 | 2021 | |
| Jazz Pharmaceuticals INC. | $11.90 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Kerasidis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.